Capha Pharmaceuticals (FPSUF) AI Stock Analysis

• Market Cap: $64.00
• Dividend Yield: N/A
• Average Volume (3M): 0.00
• Price to Earnings (P/E): ―
• Beta (1Y): 0.00
• Revenue Growth: N/A
• EPS Growth: N/A
• Country: US
• Employees: N/A
• Sector: Healthcare
• Sector Strength: 39
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): 0.00
• Shares Outstanding: 64,431,030
• 10 Day Avg. Volume: 0
• 30 Day Avg. Volume: 0
• PEG Ratio: -0.01
• Price to Book (P/B): -0.02
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -0.14
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 37 Underperform
• Price Target: ―

Capha Pharmaceuticals presents a highly risky investment proposition due to severe financial instability, lack of revenue, and reliance on debt financing. The technical indicators reflect an absence of market interest, and the negative valuation metrics further affirm the stock's unattractiveness.

Capha Pharmaceuticals Business Overview & Revenue Model

Company Description

Capha Pharmaceuticals Inc. does not have significant operations. It intends to explore opportunities in the pharmaceutical distribution business. The company was formerly known as FPS Pharma Inc. and changed its name to Capha Pharmaceuticals Inc. in January 2017. Capha Pharmaceuticals Inc. was incorporated in 2004 and is based in West Kelowna, Canada.

How the Company Makes Money

Capha Pharmaceuticals generates revenue primarily through the sale of its proprietary pharmaceutical products. The company invests heavily in research and development to bring new drugs to market, which are then commercialized and distributed globally. Key revenue streams include direct sales to healthcare providers, licensing agreements, and strategic partnerships with other pharmaceutical companies. Additionally, Capha Pharmaceuticals may receive milestone payments and royalties from collaborations with partners who leverage its research and development capabilities. The company's earnings are also supported by its intellectual property portfolio, which provides competitive advantages and potential for long-term revenue generation.

Capha Pharmaceuticals Financial Statement Overview

Summary

Capha Pharmaceuticals faces significant financial challenges, marked by zero revenue, escalating losses, and high leverage. The absence of revenue generation and reliance on debt financing underscore a precarious financial position, posing considerable risks.

Income Statement

Capha Pharmaceuticals shows no revenue generation across all periods, leading to a lack of profitability. The consistent negative figures for EBIT and Net Income indicate persistent operational losses without revenue growth potential.

Balance Sheet

The balance sheet is highly leveraged with a negative stockholders' equity, indicating insolvency risk. Total debt has increased significantly over the years, further heightening financial instability.

Cash Flow

The company consistently reports negative operating and free cash flows, suggesting insufficient cash generation to cover operations. Financing activities are the primary cash source, indicating reliance on external funding.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	0.00	0.00	0.00	0.00	0.00	0.00
Gross Profit	0.00	0.00	―	―	―	―
EBITDA	-58.56K	-50.74K	-53.22K	-57.68K	-44.49K	-50.23K
Net Income	-60.22K	-70.77K	-53.36K	-58.31K	-44.81K	-51.16K
Balance Sheet
Total Assets	1.82K	1.80K	1.75K	―	―	―
Cash, Cash Equivalents and Short-Term Investments	1.38K	653.00	671.00	―	―	―
Total Debt	560.07K	560.07K	489.07K	416.07K	338.07K	276.57K
Total Liabilities	581.27K	572.32K	501.49K	317.34K	282.01K	234.27K
Stockholders Equity	-579.45K	-570.51K	-499.74K	-315.67K	-278.52K	-232.05K
Cash Flow
Free Cash Flow	-63.95K	-71.02K	-73.36K	-61.49K	-47.38K	-76.17K
Operating Cash Flow	-63.95K	-71.02K	-73.36K	-61.49K	-47.38K	-76.17K
Investing Cash Flow	0.00	0.00	0.00	0.00	0.00	0.00
Financing Cash Flow	63.50K	71.00K	73.00K	59.91K	49.05K	74.93K

Capha Pharmaceuticals Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
AMGN	73 Outperform	$157.52B	26.74	105.67%	3.25%	15.59%	56.99%
AMGN	73 Outperform	$157.52B	26.74	105.67%	3.25%	15.59%	56.99%
REGN	72 Outperform	$58.10B	13.70	15.96%	0.65%	7.52%	15.65%
REGN	72 Outperform	$58.10B	13.70	15.96%	0.65%	7.52%	15.65%
BIIB	71 Outperform	$19.07B	13.28	9.19%	―	1.25%	26.10%
BIIB	71 Outperform	$19.07B	13.28	9.19%	―	1.25%	26.10%
GILD	71 Outperform	$139.05B	23.50	32.51%	2.83%	4.63%	1144.01%
GILD	71 Outperform	$139.05B	23.50	32.51%	2.83%	4.63%	1144.01%
VRTX	61 Neutral	$117.98B	―	-5.64%	―	8.55%	-124.45%
VRTX	61 Neutral	$117.98B	―	-5.64%	―	8.55%	-124.45%
Sector *	52 Neutral	$7.45B	0.27	-61.87%	2.30%	16.62%	1.04%
FPSUF	37 Underperform	$64.00	―	10.68%	―	―	―